Millennium Management
NEUP

Millennium Management’s Neuphoria Therapeutics NEUP Stock Holding History

Millennium Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,329
Closed -$216K – 6584
2025
Q3 		$216K Buy
+18,329
New +$170K ﹤0.01% 5508

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management's NEUP Position: Q4 2025 in Review

Millennium Management sold out of Neuphoria Therapeutics (NEUP) in Q4 2025, closing a stake of 18,329 shares — an estimated $216K sold.

Millennium Management first reported a position in NEUP in Q3 2025 and held it in 1 quarter. The position peaked at $216K in Q3 2025. 21 funds tracked by Wall St. Rank hold NEUP as of Q4 2025.

  • Millennium Management reported no remaining Neuphoria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Millennium Management sold 18,329 Neuphoria Therapeutics shares in Q4 2025, an estimated $216K.
  • Millennium Management first reported a position in Neuphoria Therapeutics in Q3 2025 and held it in 1 quarter.
  • Millennium Management's Neuphoria Therapeutics position peaked at $216K in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.